Roche's Vabysmo Lifts Vision By 4.6 Letters In Untreated nAMD Eyes And 8.2 In DME After 12 Months In Real-World VOYAGER Data Presented At EURETINA

Roche's Vabysmo demonstrated significant improvements in vision, with an increase of 4.6 letters in untreated neovascular age-related macular degeneration (nAMD) eyes and 8.2 letters in diabetic macular edema (DME) after 12 months, according to the VOYAGER real-world data presented at EURETINA. The study, which included over 5,000 patients, confirms Vabysmo's effectiveness and durability as a standard-of-care therapy without new safety concerns. Advanced AI analysis also showed rapid anatomical drying, reinforcing its clinical benefits.